Belimumab for active cryoglobulinemia vasculitis after rituximab
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Skin clinical trials.
This Phase 2 study tests belimumab (or a placebo) to see if it improves safety and disease control in adults with active cryoglobulinemia vasculitis. You may be eligible if you have had rituximab induction treatment shortly before joining, and your illness is still active.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You can sign written informed consent.
- You have active cryoglobulinemia vasculitis affecting organs like skin, joints, kidneys, nerves, brain, gut, lungs, or the heart.
- You received rituximab induction treatment within the last 6 weeks (usually 1 to 4 infusions).
- You can use reliable birth control (or abstain) during the study and for 92 days after the last dose, if pregnancy is possible.
- Your bloodwork and infection/hepatitis tests meet safety rules, including HIV negative, hepatitis B/C negative (with specific requirements).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether adding an injection called belimumab (or a placebo) to rituximab works better and is safe for adults with long-lasting immune thrombocytopenia (ITP). You may be eligible if your platelet counts stay low despite prior steroid and/or IVIG treatment and if infections, vaccines, and other health conditions meet the study rules.
This study follows patients with ANCA-associated vasculitis (a rare autoimmune disease affecting blood vessels) who receive rituximab, a medication that depletes certain immune cells. Researchers want to understand how the immune system recovers over time and whether this helps predict disease flares or relapses.
This trial tests if the drug obinutuzumab can help people with a blood vessel inflammation called cryoglobulinemia vasculitis when rituximab no longer works or causes side effects. It is a single-arm study, meaning everyone gets the new drug.
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
This Phase 2 study tests whether combining belimumab and rituximab can improve skin thickening in people with early diffuse cutaneous systemic sclerosis (dcSSc). It may help slow the disease process and improve skin symptoms, but it also requires screening for immune and infection risks.
This Phase 1 study tests how safe belimumab is for people with idiopathic CD4 lymphopenia (low protective white blood cells) and signs of autoantibodies. It aims to learn whether the treatment is tolerable and could be a future option for people with this immune condition.
Hear when a new Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.